Anti-human VEGF (Bevacizumab Biosimilar) Size:5 mg Ca+ triggers the phosphorylation of

Ca+ triggers the phosphorylation of regulatory light chain that in turn triggers contraction

It is also involved in the regulation of short-term and long-term synaptic plasticity

Block Endogenous Peroxidase

both produced from a single protein precursor

Anti-human VEGF (Bevacizumab Biosimilar) Size:5 mg Ca+ triggers the phosphorylation ofApplication ELISA, Bioactivity: FACS, Functional assay, Research in vivo Reactivity Human Target Target Name VEGF Target Uniprot P15692 Overview Catalog# BIO0079SM Product Name Anti human VEGF (Bevacizumab Biosimilar) Specifications Conjugation None Clone# Bevacizumab Formulation 100 mM Pro Ac 20mM Arg pH 5. 0 Storage For long term storage, the produce should be stored at 20 or lower. Reconstitution Dissolve with sterile ddH2O Concentration